Company profile: Nuvation Bio
1.1 - Company Overview
Company description
- Provider of oncology-focused biopharmaceutical therapies addressing unmet needs, developing oral targeted candidates including Taletrectinib (CNS-active, selective next-generation ROS1 inhibitor for ROS1-positive NSCLC), Safusidenib (potent mIDH1 inhibitor for grades 2-3 IDH1-mutant glioma), NUV-868 (BD2-selective BET inhibitor targeting BRD4), and NUV-1511 (drug-drug conjugate candidate).
Products and services
- NUV-1511: A novel drug-drug conjugate (DDC) clinical candidate leveraging the drug-conjugate class to deliver anti-cancer therapy via a unique therapeutic approach
- NUV-868: A BD2-selective oral small molecule BET inhibitor that inhibits BRD4 and is engineered to reduce dose-limiting toxicities seen with non-BD2 selective BET inhibitors
- Safusidenib: A targeted, oral, potent inhibitor of mutant IDH1 (mIDH1) evaluated in a global Phase 2 trial for patients with grades 2 and 3 IDH1-mutant glioma
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Nuvation Bio
Immune-Onc Therapeutics
HQ: United States
Website
- Description: Provider of therapeutic antibodies for cancer treatment, developing IO-202, a humanized IgG1 targeting LILRB4 to deplete LILRB4-expressing cells in blood cancers, autoimmune, and inflammatory diseases; IO-108, a fully human IgG4 targeting LILRB2 to block cancer-associated immune suppression in solid tumors; and IO-312, a bispecific targeting LILRB4 and CD3 for AML and other hematologic malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immune-Onc Therapeutics company profile →
Five Prime Therapeutics
HQ: United States
Website
- Description: Provider of cancer treatment biotechnology, discovering and developing novel therapeutic proteins and antibodies by systematically screening all relevant human proteins to find the best for each clinical indication, enabled by its ProScreen Engine for rapid production and screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Five Prime Therapeutics company profile →
Seagen
HQ: United States
Website
- Description: Provider of monoclonal antibody-based therapies and advanced antibody-drug conjugate technology focused on improving patient outcomes in cancer and autoimmune diseases. Lead program SGN-35 is in a pivotal trial for patients with relapsed or refractory Hodgkin lymphoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seagen company profile →
Accession Therapeutics
HQ: United Kingdom
Website
- Description: Provider of immuno-oncology therapeutics based on Trocept, a stealth virus platform engineered to selectively enter cancer cells while bypassing healthy cells to deliver broad, potent payloads and minimize systemic toxicity, targeting hard-to-treat cancers. Pipeline includes TROCEPT-01 (immune checkpoint inhibitor), TROCEPT-02 (universal bispecific immune activator), and other targeted programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Accession Therapeutics company profile →
Elevation Oncology
HQ: United States
Website
- Description: Provider of precision medicines as a clinical-stage biopharmaceutical company, developing EO-3021, an antibody-drug conjugate targeting Claudin 18.2 for advanced/metastatic solid tumors, particularly gastric and gastroesophageal junction adenocarcinoma, and Seribantumab, an anti-HER3 monoclonal antibody for NRG1 fusion-positive tumors; conducts clinical trials and offers compassionate use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elevation Oncology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Nuvation Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Nuvation Bio
2.2 - Growth funds investing in similar companies to Nuvation Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Nuvation Bio
4.2 - Public trading comparable groups for Nuvation Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →